A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial.
J Infect Dis
; 202(5): 675-80, 2010 Sep 01.
Article
en En
| MEDLINE
| ID: mdl-20632888
ABSTRACT
A double-blind, randomized, controlled trial involving 706 adults was conducted to evaluate the immunogenicity and safety of different dosages of whole-virion or split-virion H1N1 influenza vaccines with or without aluminum adjuvant. A rapid and strong immune response was induced at day 14 after the first injection. The seroprotection rates ranged from 72.7% (95% confidence interval [CI], 62.7%-81.1%) for 5-microg whole-virion aluminum formulation to 97.0% (95% CI, 90.9%-99.7%) for 30-microg split-virion nonaluminum formulation. All formulations were well tolerated. The incidences of mild, moderate, and severe reactions were 71 (10.1%), 15 (2.1%), and 1 (0.1%) of 706 reactions, respectively. The 15-microg split-virion formulation had the best immunogenicity and safety.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Vacunas contra la Influenza
/
Adyuvantes Inmunológicos
/
Gripe Humana
/
Subtipo H1N1 del Virus de la Influenza A
/
Hidróxido de Aluminio
/
Anticuerpos Antivirales
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Humans
/
Middle aged
Idioma:
En
Año:
2010
Tipo del documento:
Article